Sleeping pill claims disturb NAD
This article was originally published in The Tan Sheet
Urban Nutrition agrees to discontinue certain ad claims for its RestAid dietary supplement, including reference to the product as a "non-prescription sleeping pill," following a NAD review. The decision released Oct. 19, under NAD's CRN-supported work, concludes claims in print and online ads suggesting the product helps consumers fall asleep faster and deeper - and allows them to awake more refreshed - were unsupported by evidence in the record. Rather, NAD recommends limiting such claims to the product's melatonin ingredient. Further, the CBBB division found no evidence to support the claim the product's delivery system "gets the nutrients into the bloodstream much quicker than other supplements." New York-based Urban Nutrition, which agreed to modify its ads, previously was the subject of an Electronic Retailing Self-Regulation Program review that found the firm failed to disclose its material connection to products it endorsed on a review website it operated (1"The Tan Sheet" Aug. 17, 2009, In Brief)
You may also be interested in...
The operator of WeKnowDiets.com and other Web sites should clarify that it markets weight-loss supplement MiracleBurn - featured as the "most popular" product and a "customer choice award" winner on the site - according to the Electronic Retailing Self-Regulation Program. Urban Nutrition presented WeKnowDiets.com as a review forum for diet products, though a challenger argued to ERSP that the site "is premised on a deliberate intent to mislead consumers" by disguising ads as independent product reviews. The CBBB program recommended Aug. 11 that the firm disclose its material connection to the products it endorses. New York-based Urban Nutrition said it will "follow the ERSP's recommendations to reinforce several aspects of effective disclosure methods.
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.